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ReviewOne hundred years ago, Edwin E. Goldmann discovered
the blood–brain barrier (BBB) using trypan dyes. These
dyes were developed and named by Paul Ehrlich during
his search for drugs to kill African trypanosomes (extra-
cellular parasites that cause sleeping sickness) while
sparing host cells. For Ehrlich, this was the first strategy
based on the ‘chemotherapy’ concept he had introduced.
The discovery of the BBB revealed, however, the diffi-
culties in drug delivery to the brain. Mechanisms by
which parasites enter, dwell, and exit the brain currently
provide novel views on cell trafficking across the BBB.
These mechanisms also highlight the role of pericytes
and endocytosis regulation in BBB functioning and in
disrupted BBB gating, which may be involved in the
pathogenesis of neurodegeneration.
Trypanosome attacks unveiled the BBB
As a drawbridge, the BBB protects the gatehouse of the
central nervous system (CNS) castle, surrounded by the
moat of the bloodstream. The castle loopholes are very tight,
represented by tight junctions of cerebral microvessels
(capillaries and postcapillary venules), assisted by pericytes
and astrocyte endfeet, and their respective basement mem-
branes, as watchmen (Figure 1). In 2014, our knowledge of
the BBB drawbridge has turned 100 years. Although some of
the experiments that led to the discovery of the BBB may be
known, it is certainly less well known that this pillar of
knowledge in neuroscience is intertwined with the history of
a deadly tropical disease, sleeping sickness or human Afri-
can trypanosomiasis. This disease is caused by the extracel-
lular protozoan African trypanosome, which is capable of
entering the CNS by crossing the BBB.
We owe the discovery of the BBB to attempts to deliver
drugs to the brain for treatment of African trypanosome
infections. These studies also contributed to the later
development of the concept of endocytosis, which is a core
principle in cell biology and in neurobiology. Our under-
standing of regulated endocytosis in the BBB and in try-
panosomes is now rapidly evolving in parallel, and it is
largely forgotten that such findings originated from the
same studies 100 years ago. In this review, we highlight0166-2236/
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persist in the CNS parenchyma, focusing on the BBB in
view of current studies on trypanosome–brain interactions.
Because trypanosomes were pivotal to the discovery of the
BBB, we highlight how BBB research may repay trypano-
some research. This also opens questions on cell trafficking
mechanisms in and out of the BBB, on the importance of
endocytotic mechanisms for drug targeting, and on the
potential role of disturbed BBB gating in the pathogenesis
of neurodegeneration.
The story of rejected bullets
Central to development of the ‘chemotherapy’ concept at
the beginning of the 20th century was the use of colored
drugs to visualize and distinguish microbes (to kill) from
host cells (to spare). African trypanosomes represented the
first target for chemotherapy, and drugs called ‘trypan
dyes’ (a name derived from the parasites) were used. These
dyes not only played a crucial role in the detection of the
BBB, but also became important markers of cell viability
because they do not pass intact cell membranes, playing a
key role also in the concept of endocytosis.
Trypanosomes and African trypanosomiasis: the search
to cure a lethal infection
Between 1901 and 1903, an outbreak of the lethal disease
sleeping sickness affected about 80% of the population on
the Northern side of Lake Victoria. A commission (the
epidemiologist Cuthbert Christy, the parasitologist George
Low, and the bacteriologist Aldo Castellani) was sent to
Entebbe, Uganda, in July 1902. Using a hand-driven cen-
trifuge and a moderately powerful microscope, Castellani
observed trypanosomes in the cerebrospinal fluid (CSF) of
patients [1]. This was surprising because trypanosomes
were at that time only known to be the cause of ‘nagana’, a
disease endemic among south-African cattle, as discovered
by Sir David Bruce. The causative agents were called after
him, Trypanosoma (T.) brucei, a denomination derived
from the Greek ‘trypanon’ (drill), probably due to the
rotating movement of the parasite, which is equipped with
a flagellum, in the bloodstream.
Because this was the time of colonialism, it became of
public interest to find a remedy. Considering that protozoa
could be more susceptible to chemical agents than bacteria,
Paul Ehrlich (1854–1915) engaged in research based on the
concept of chemotherapy he had introduced [2]. Inspired by
treatment of malaria with quinine and by the attempts, by
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Figure 1. Schematic representation of the blood–brain barrier (BBB) and roles
exerted by pericytes. At the interface between the systemic circulation and the
central nervous system (CNS), the BBB is composed of highly specialized and
polarized endothelial cells with tight junctions sealing the intercellular clefts,
basement membranes, pericytes, astrocyte endfeet, with anchoring
transmembrane proteins, which establish communication with neurons in the
neurovascular unit. Astrocyte endfeet actually envelop almost the entire abluminal
surface of CNS microvessels. Novel data indicate that pericytes, embedded within
the endothelial cell-derived basement membrane, are involved in the control of
endothelial transcytosis and tight junction opening. Adapted from [65].
Review Trends in Neurosciences June 2014, Vol. 37, No. 6mice infected with trypanosomes from cattle suffering from
‘nagana’, Ehrlich used trypanosomes as his first target [2].
A donation by Mrs Franziska Speyer had provided the
funding for the chemotherapy institute Georg Speyer-
Hause in Frankfurt devoted to Ehrlich’s research to re-
place empirical therapy with a ‘chemotherapia specifica’ by
which parasites could be killed without causing major
damage to the organism [3]; thereby, ‘money’ could be
added to ‘patience’, ‘skill’, and ‘luck’, the four most impor-
tant factors for fruitful research as defined by Ehrlich [4].
To see or not to see: trypan dyes
To enable distinction between targets (microbes) and non-
targets (host cells), Ehrlich searched for suitable colored
compounds that could stain and kill parasites like
‘bewitched bullets’. Methylene blue, which was in common
use, was found to be too toxic to the host. In his first series
of experiments, Ehrlich therefore turned to the so-called
azo dyes derived from benzopurpurins. After testing sev-
eral azo dyes, a water-soluble red compound was found to
be trypanocidal with a tolerable low toxicity and was
christened ‘trypanroth’ (‘trypan red’) [2]. For his studies,
Ehrlich received as gifts guinea pigs infected with a horse
pathogenic trypanosome strain, T. equinum, which causes
‘mal de caderas’ in South America. Mice injected with blood
from these guinea pigs died within 4–5 days, but injection
of trypan red within 3 days of infection could cure the mice
[2]. This marked the first successful ‘chemotherapy’: killing
a microbe with a specifically designed and selected drug.
However, relapses of the infection occurred up to several
months after treatment, and attempts to treat T. brucei
strains failed, as did trials with about 50 alternatives to
trypan red. The studies therefore came to an end in 1905
[3]. Ehrlich then focused, until his death, on the treatment326of syphilis with the arsenical compound Salversan. In the
meantime, blue and violet trypan dyes had been synthe-
sized by the Bayer Company. These dyes showed poten-
tially more promising effects, as observed by Nicolle and
Mesnil at the Pasteur Institute [3,5]. Among them, trypan
blue became a vital staining agent destined to be a protag-
onist in the discovery of the BBB.
CNS regions ‘white as snow’ turning blue: the discovery
of the BBB
Edwin E. Goldmann (1862–1913) (Figure 2), a native of
South Africa, studied medicine in London followed by visits
to German universities (Breslau and Frankfurt) before
devoting himself at a lay worker’s institution in Freiburg
as a surgeon of tumors. In his studies on experimental
tumors, Goldmann performed vital staining using dyes
devised by Ehrlich. Based on this work, he noted that
trypan blue showed the lowest toxicity and spread fastest
in the body. In his first series of experiments, Goldmann
observed that following systemic injections of trypan blue
in several species (frogs, mice, rats, guinea pigs, rabbits,
dogs, and monkeys) the whole animals were rapidly
stained blue. However, the brain and spinal cord remained
‘white as snow’, with the exception of the choroid plexus [6].
The question therefore arose: was the lack of staining of the
CNS due to lack of dye affinity or to a failure of dye entry
into the brain parenchyma? This question was solved in the
next set of experiments on young rabbits [7].
Following injections of trypan blue into the subarach-
noid space at lumbar level or in the cisterna magna, the
CNS regions to which the dye could rapidly flow (spinal
cord, brainstem, cerebellum, and basal forebrain) turned
out to be stained blue (Figure 3). This showed that lack of
CNS tissue staining after systemic injections of the dye
was due to lack of dye penetration from the blood into the
CNS and not to lack of dye affinity. The existence of a
blood–brain and blood–CSF barrier was for the first time
clearly visualized and demonstrated [7].
Enemies hiding behind the BBB
Why could Ehrlich not prevent relapses by treating try-
panosome-infected rodents with trypanocidal trypan dyes?
The answer to this question came, after decades, from a
series of experiments by Frank Jennings and collaborators
in Glasgow [8]. They treated T. brucei-infected mice with
the trypanocidal drug diminazene aceturate (an aromatic
diamidine used in veterinary medicine to treat early-stage
African trypanosomiasis). Although the parasites were
eliminated from the blood, the infections relapsed in all
mice 4–7 weeks later. Injections of homogenates from the
brain of treated mice, taken before the relapses, could
successfully transmit the infection to naı¨ve mice, whereas
injections of other tissues or blood could not. This meant
that the parasites could hide in the brain behind an intact
BBB, being inaccessible to diminazene, which does not
cross the BBB. The findings imply that Ehrlich’s failure
in preventing relapse was due to the fact that trypan dyes
do not cross the BBB.
This observation raises three questions. (i) How can
trypanosomes enter the brain parenchyma and persist
behind an intact BBB? (ii) How can trypanosome growth
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Figure 2. Portrait of Edwin Ellen Goldmann. Born in 1862 in Burgherdorp, South
Africa, Goldmann died of cancer in 1913 in Freiburg im Bresgau, Germany, 2
months after his contribution to the discovery of the blood–brain barrier (BBB) [7].
Goldmann is not described as a student or associate of Ehrlich, but they should
have been in contact. Goldmann’s experiments that led to the detection of the BBB
were done with the financial support of the late Sir Julius Wernher and others, and
with the technical and intellectual assistance of Marie Schmelzer, a lay worker.
(Image in the public domain: http://de.wikipedia.org/wiki/Edwin_Goldmann).
(A)
(B)
TRENDS in Neurosciences 
Figure 3. Illustration of Goldmann’s seminal discovery of the blood–brain barrier
(BBB) in 1913. Overview of the central nervous system (CNS) of a young rabbit
injected with 0.5 ml of a 0.5% trypan blue solution into the lumbar ‘cul-de-sac’.
Table III from [7]; (A) dorsal and (B) ventral view. The whole spinal cord and
brainstem are stained blue, as are the optic nerves, sclerae, and olfactory areas
(i.e., the regions to which the dye could rapidly flow). Note that Goldmann did not
perform injections of the dye into the cerebral ventricles or the brain parenchyma.
The illustration clearly shows that the lack of trypan blue staining of the CNS
following systemic injections of the dye was not due to lack of dye affinity for the
CNS, but instead to lack of dye penetration into the brain parenchyma from the
blood and choroid plexus, and therefore to a permeability problem, that is, to the
existence of a blood–brain and blood–cerebrospinal fluid (CSF) barrier. By two-
photon laser scanning microscopy, it has been recently visualized that substances
of low molecular weight (such as trypan blue, which in the CSF is not bound to any
serum protein), which circulate in the CSF, rapidly enter the CNS interstitium from
both the pial surface and spaces around arteries/arterioles, whereas those of high
molecular weight are confined to the paravascular spaces [41].
Review Trends in Neurosciences June 2014, Vol. 37, No. 6in the brain be controlled so that the parasites stay alive
and do not cause a rapidly overwhelming infection? (iii)
How can the unicellular trypanosomes exit the brain to
cause a relapse?
Challenges in parasite trafficking in and out the brain:
fooling the drawbridge?
Parasite entry and brain immune response
In experimental rodent models, T. brucei subspecies ap-
pear in the choroid plexus soon after infection. At the same
time, parasites lodge in the circumventricular organs
(CVOs) and dorsal nerve root ganglia which, like the
choroid plexus, have fenestrated endothelia and lack tight
junctions. Trypanosomes also appear in the leptomeninges
early after infection [9]. However, it is not clear whether
lodging in the meninges reflects passage from the choroid
plexus and subsequent spread in the CSF, as suggested by
Goldmann [7] and recently by Wolburg et al. [10], or direct
crossing of leptomeningeal vessels, more permeable to
macromolecules than brain parenchymal vessels [11].
The lack of an astrocyte-derived parenchymal basementmembrane in meningeal vessels may also facilitate the
passage of pathogens into the meninges and subarachnoid
space.
Further T. brucei passage across the cerebral microvas-
culature (Figure 4) shows large temporal variations depen-
dent on the host species and strain, as well as on the T.
brucei subspecies. Remarkably, brain invasion by trypano-
somes is not related to the level of parasitemia but to the
host immune response [12]. For instance, treatment with
minocycline, a drug that reduces the immune response in327
(A) WT GLUT-1/Tbb 13 dpi WT GLUT-1/Tbb 29 dpiIFN-γ–/– Laminin β1/ Tbb 20 dpi(B) (C)
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Figure 4. African trypanosomes in the brain. (A) Trypanosoma brucei brucei (Tbb; red) within brain capillaries (green; cerebral endothelial cells are stained by glutamate
transporter-1, GLUT-1) in wild type (WT) mice early after infection (13 days post-infection, dpi). (B) Accumulation of trypanosomes (red) and white blood cells (seen as
silhouettes) as ‘cuffs’ within basement membranes (green; labelled with antibodies against laminin b1 that is present in both the endothelial and astrocytic basement
membranes) of a larger intracerebral vessel in an interferon-g (IFN-g)-deficient mouse at 20 dpi. (C) Numerous extravascular trypanosomes (red) in the white matter at the
late stage of infection (green; cerebral endothelial cells). The plate illustrates that passage of trypanosomes from the blood into the brain through the outer parenchymal
basement membrane is dependent on immune response molecules induced by the infections. Scale bar: 10 mm. Reproduced, with permission, from [76].
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sion [13]. In particular, the T helper 1 (Th1) immune
response increases trypanosome neuroinvasion: in the
absence of interferon (IFN)-g and T cells, parasite entry
into the brain parenchyma is greatly reduced although
parasitemia levels may be increased [9].
It should be emphasized that invasion of T cells and
trypanosomes occurs at the postcapillary venules [9],
where there is a perivascular space, and not at the capil-
lary level, which is usually the focus in studies on BBB
properties [14]. To invade the brain parenchyma, circulat-
ing T cells have to attach to endothelial adhesion mole-
cules, and then pass either through openings of tight
junctions or transendothelially to meet the next hurdle
of the basement membranes [15,16]. Whether trypano-
somes pass in vivo via tight junction openings or transcy-
tosis remains elusive; both possibilities have been
suggested in vitro [17,18]. In vitro models of the BBB,
however, do not reflect the complexities of the in vivo
situation [19], not the least those of postcapillary venules.
The endothelial cells of cerebral postcapillary venules
are enwrapped by two basement membranes: the endothe-
lial membrane and the parenchymal basement membrane,
also called the astrocytic basement membrane [14,16]. T
cell penetration depends on the composition of laminin
molecules in these membranes. Laminin a5 chains in the
basement membranes around capillaries do not permit T
cell invasion, whereas laminin a4 chains, at postcapillary
sites, do. In addition, the astrocytic basement membranes
(laminin a1 and a2 chains) must be focally ‘opened’ by
activated matrix metalloproteases to allow T cell passage;
if this does not occur, T cells wait ‘on hold’ as cuffs around
the vessels [14,16].
Trypanosomes closely follow this series of events in
their brain invasion [9], which is initiated by molecules
released by the innate immune response. Via an initial
release of low levels of C–X–C motif chemokine 10
(CXCL10), the innate immune response communicates
with the adaptive immune response [20]. This chemokine
may facilitate the recruitment of trypanosome-sensitized T328cells into the brain to recognize trypanosome antigen-pre-
senting cells, for example, dendritic cells. Sensitized T cells
are thereby activated to secrete IFN-g [20], which stimu-
lates CXCL10 secretion accelerating the process of try-
panosome neuroinvasion [21].
This chain of events is similar to that described for brain
infections with lymphocytic choriomeningitis virus [22],
pointing to a more general role of CXCL10 in the crosstalk
between the innate and adaptive immune response in the
CNS. In addition, CXCL10 is not only needed for the
recruitment and/or retention of antigen-specific T cells
in the brain, but can also enhance T cell migration speed,
thus shortening the time to find rare targets. This is the so-
called ‘Le´vy walk’, observed during brain infections with
the intracellular parasite Toxoplasma gondii [23]. How the
extracellular trypanosomes move within the brain paren-
chyma in relation to T cells and dendritic cells is, therefore,
intriguing to determine.
An accelerated brain invasion of trypanosomes would
not be compatible with survival of the host, needed for
transmission to other individuals through the parasite
vector (the tsetse fly). Therefore the parasite passage
across the BBB must be controlled. However, there is a
gap in knowledge on molecular closure mechanisms of the
CNS gate after its opening. Interestingly, administration
of exogenous nitric oxide can reduce vascular leak in cere-
bral malaria [24–26], and may, speculatively, also play a
role in ‘closing the door’ behind trypanosomes entering the
brain parenchyma.
Surviving within the CNS castle: parasite persistence
How do trypanosomes persist in the brain? Although the
BBB protects them from antibodies circulating in the
bloodstream, the CNS castle may not be secure for the
parasites, whose survival may be endangered by still
undefined trypanotoxic constituents circulating in the
CSF [10]. The search for such host-derived factors in the
CSF could lead to the identification of molecules to combat
the parasite. In addition, the CNS castle is equipped with
devices against enemies and, in particular, a number of
Review Trends in Neurosciences June 2014, Vol. 37, No. 6neuropeptides are antimicrobial, showing high affinity to
bacterial, but not mammalian, cell membranes [27]. For
example, neuropeptide Y produced in the olfactory epithe-
lium [28] can prevent bacteria from entering the CNS along
olfactory pathways [29]. In vitro, several neuropeptides
(e.g., vasoactive intestinal peptide, adrenomedullin, and
urocortin) are trypanolytic [30], but only at relatively high
concentrations (mM), and their role in vivo remains to be
investigated. The neuropeptide substance P can, however,
at physiological concentrations reduce the severity of try-
panosome-induced neuroinflammation [31].
To survive for extended periods of time in the brain
castle without demolishing it by killing the host, the life of
trypanosomes may be balanced by both growth-inhibiting
and -promoting molecules in the environment. During
their persistence in the brain, trypanosomes have been
observed mainly in the olfactory bulbs and cerebellum
[32,33], where turnover of small granular neurons occur.
Cell growth-promoting factors in these regions could po-
tentially also favor pathogen survival, an interesting topic
that needs to be investigated. In support of this assump-
tion, it should also be considered that, at the periphery,
trypanosomes can persist in the testes [34], which are
equipped with a blood–testis barrier and produce a number
of cell growth-regulating factors [35].
How can cells exit the brain? Escape routes
A proportion of trypanosomes should remain in proliferat-
ing (slender) form to be able to expand and cause relapses
upon exiting the brain (Figure 5). T. brucei brucei can cross
the BBB from the abluminal to the luminal side of endo-
thelial cells in vitro [36], but this remains to be verified in
vivo. The direction of parasite swimming, due to movement
of the flagellum forward or backward according to tissue
densities (Figure 5), could also influence trypanosome
trafficking in and out the brain.Aached ﬂagellum
Base of ﬂagellum
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Figure 5. Swim or sink: trypanosome as a drill. Illustration of Trypanosoma brucei
cell architecture. The T. brucei human pathogenic subspecies are spread by the
vector (tsetse fly) and exist in the mammalian host in two forms, the rapidly
dividing (5–6 hours) slender form and the nondividing stumpy form, which can be
transmitted back to the fly. Slender trypanosomes secrete a molecule that induces
the transformation into the stumpy form [77] to prevent overwhelming infections
that could rapidly kill the host. Trypanosomes prosper in the bloodstream. Slender
trypanosomes are pulled forward in rotational movements, like drills, by the planar
beat of their flagellum and reach their maximum velocity in the cell density of
streaming blood [78]. If cell density increases, the flagellar beats are reversed and
trypanosomes swim backward not to get trapped [78]. The motility of
trypanosomes in the dense brain tissue remains to be explored. Reproduced,
with permission, from [78].Although T cells facilitate trypanosomes entry into the
brain, different mechanisms may be involved in trypano-
some exit from the brain. In general, T cells are killed in the
tissues, for example, by Fas ligand-induced apoptosis,
when their mission is accomplished [37]. Interestingly,
in rabies, a severe viral CNS infection, the killing of T
cells is turned on prematurely by the rabies virus in
neurons to evade virus elimination [38]. Antigen-present-
ing cells may cross the BBB after injection into the brain
parenchyma [39], and a population of such cells can pro-
trude dendritic extensions across the BBB into the vascu-
lar lumen [40]. It is not known, however, whether such a
mechanism could provide an escape route for trypano-
somes into the blood.
Goldmann [7] noted that trypan blue injected into the
CSF of dogs diffused into the brain along perivascular
spaces, but also appeared in deep cervical lymph nodes,
suggesting a direct communication between brain and
lymphatics. Therefore, a lymphatic drainage of the brain
was proposed in addition to the classical drainage of CSF
into the blood through arachnoid villi and granulations.
The CSF may be reached by molecules from the brain
parenchyma via paravenous drainage pathways. Although
CSF influx into the interstitial spaces of the brain paren-
chyma is partly driven by arterial pulse waves along
periarterial spaces, outflux of soluble molecules is driven
by the water channel aquaporin-4 in astrocytic endfeet
[41]. Cortical interstitial spaces increase during sleep fa-
cilitating the clearance of soluble metabolites [42], but it is
not known whether interstitial spaces could become suffi-
ciently large to facilitate the propelling of cells, such as
trypanosomes, into the CSF.
Once in the CSF, antigen-presenting cells could reach
the nasal and lumbar lymphatics via the channels that
drain CSF from the subarachnoid space along olfactory and
spinal nerves [43]. This could provide an exit route for
trypanosomes, especially from the olfactory bulbs, where
they may persist before relapses [32,33] having access to
nasal lymphatics through the cribriform plate.
An alternative pathway suggested for soluble molecules
would lead directly to cervical lymph nodes from the brain
parenchyma along basement membranes between smooth
muscle cells of arterioles and arteries by contrary waves
following arterial pulse waves [43]. This, however, is an
unlikely pathway for the escape from the brain of cells,
including trypanosomes, which have not been seen along
such basement membranes.
The host–pathogen duel manipulates brain function
What do trypanosomes do in the brain? A prominent sign of
sleeping sickness is represented by sleep/wake distur-
bances, with periods of sleep during daytime and insomnia
at night, as well as a fragmented sleep pattern with
narcolepsy-like sleep episodes [44,45]. These alterations
differ from the somnolence that occurs in so-called ‘sick-
ness behavior’ during systemic infections.
Trypanosomes produce prostaglandin D2, which can
induce slow-wave sleep following intracerebroventricular
injections, and the release of this molecule could play a role
in sleep changes during the infection [10]. However, the
total sleep time during a 24-hour period is not increased in329
Box 1. Trypanosome neuroinvasion governs therapy
decisions to kill the parasite or the host
Decisions on life or death
The crossing of an intact BBB by African trypanosomes is an
important consideration for therapy decisions. Presently, finding
trypanosomes and/or more than five white blood cells in the CSF is
used as marker of parasite neuroinvasion. Suramin and pentamidine
are drugs of choice for treatment of early-stage T. brucei rhoden-
siense and T. brucei gambiense infections, respectively, but they do
not cross the BBB. More toxic drugs such as arsenical compounds
(which can be lethal), eflornithine, or eflornithine in combination with
nitrofurmox are in use for late-stage therapy [79,80]. However,
experimental findings have shown that trypanosomes can appear in
the meninges (and the CSF) early after infection [10,32,81], when the
animals are still sensitive to early-stage drugs.
Signs of nervous system involvement may be misleading for the
staging of sleeping sickness, because some of them (neuropathic
pain and sleep changes) may appear early after infection [82] when
in experimental models trypanosomes are still mainly localized to
dorsal root ganglia and CVOs and accessible to drugs that do not
cross the BBB. Better objective clinical measures, including
biomarkers for disease staging, are therefore a priority. Neopterin,
which is a stable product of IFN-g-stimulated macrophages [83,84],
and the IFN-g-inducible chemokine CXCL10 could be biologically
meaningful biomarkers [85–87], because IFN-g facilitates trypano-
some passage across the BBB [9].
Targeting trypanosome endocytosis
Endocytosis at the trypanosome flagellar pocket is currently being
explored for the targeted delivery of trypanocidal molecules [52].
The receptor for suramin (the colorless derivative of trypan dyes
synthesized in 1916, kept as a war secret and released for clinical use
only in the early 1920s) has been identified in an invariant surface
glycoprotein at the flagellar pocket. Following endocytosis, this
glycoprotein is delivered to lysosomes where suramin, once free,
inhibits cellular processes, similarly to trypan blue. This explains
why trypan compounds affect trypanosomes (high endocytosis) but
not host cells (low endocytosis), that is, the basis for Ehrlich’s
chemotherapy concept [52]. New drugs are now developed, and
these include nanobodies that elicit trypanocidal effects by en-
docytosis inhibition [88–90], acting as the ‘bewitched bullets’ Ehrlich
envisaged.
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early localization of trypanosomes to CVOs followed by
invasion of parasites and inflammatory cells into dience-
phalic areas could affect the functioning of the master
circadian clock (the suprachiasmatic nucleus) and sleep/
wake-regulating cell groups in the hypothalamus [9].
Whether sleep/wake alterations or other behavioral
changes caused by T. brucei infections pose any advantage
for parasite spread by the tsetse fly remains to be clarified
[10]. This question is of interest to the current debate as to
whether behavioral changes caused by persistent parasitic
brain infections can favor parasite survival, for example, in
Toxoplasma gondii infections [46]. This parasite may ma-
nipulate intermediate host behavior to enhance the risk of
the host to become victim of a predator and, thus, increase
its own dissemination [47,48].
The key role of endocytosis
Endocytosis in trypanosomes
As mentioned above, trypan blue became a classical mark-
er for cell viability because it cannot pass intact cell
membranes and does not stain most living cells. The
question how trypan dyes enter trypanosomes and kill
them has recently found an explanation. Trypanosomes
show a massive endocytosis, which enables them to remove
antibodies against the variant surface glycoproteins (VSG)
that cover their surface. Endocytosis occurs in large cla-
thrin-coated vesicles in the so-called flagellar pocket at the
posterior end of the parasite [49] (Figure 5). The whole pool
of VSG can be turned over within minutes and the speed is
accelerated by the parasite swimming in the bloodstream
[50]. The removal of attached antibodies against VSG by
endocytosis could be a means to evade the humoral im-
mune response, in addition to the pre-programmed
switches of the VSG coats [51]. This makes conventional
VSG-specific antibodies, which depend on complement
activation, inefficient in killing trypanosomes. Because
trypan blue is incorporated by endocytosis, the dye is taken
up by trypanosomes in large amounts and labels them
rapidly blue, in contrast to most host cells with a much
lower level of endocytosis. Endocytosis at the parasite
flagellar pocket is currently a target for the development
of antitrypanosome drugs [52] (Box 1).
Endocytosis and pericytes in the BBB
Tight junctions linking cerebral microvascular endothelia
and the scarcity of fluid-phase endocytosis are defining
features of the BBB maintenance of brain homeostasis
[53,54]. Thus, in contrast to the exceptionally high level
of endocytosis in bloodstream trypanosomes, which pre-
vents antibodies from attacking them, cerebral endothelial
cells are endowed with remarkably low endocytosis or
transcytosis, which also prevents circulating antibodies
from entering the brain.
Pericytes, which are mesenchymal-derived cells, are key
regulators of transcytosis in cerebral endothelia [55]. Peri-
cytes encircle cerebral endothelial cells, enwrapped in the
same basement membrane (Figure 1), and can affect trans-
cytosis in these cells during development [56], in addition
to their role in the structural integrity and vasodynamic
capacity of the BBB [57,58]. Transcytosis is highly330enhanced, while tight junctions are preserved, in peri-
cyte-deficient mice, indicating that pericytes regulate the
level of transcytosis also in adult mice [55,59] (Figure 1).
In addition to the control of transcytosis, pericytes of the
BBB can contribute to the ‘opening’ of cerebral endothelial
tight junctions (Figure 1) through the activation of a
proinflammatory cyclophilin A–matrix metalloprotease-9
pathway [60]. Interestingly, pericytes can be under the
attack of viruses, such as HIV and Japanese encephalitis
virus, which cause infections associated with neurodegen-
eration [61,62]. The question therefore arises: can pericyte-
regulated processes in the BBB contribute to dysfunctions
or destructions of neurons?
Alterations of the BBB as a gateway to
neurodegeneration?
Changes in BBB permeability, which could reflect func-
tional alterations of pericytes and tight junction opening,
have been recently suggested to precede neurodegenera-
tion and cognitive decline during aging [59], as well as in
apolipoprotein E (APOE) gene-manipulated mice [60]. Pu-
tative mechanisms for these events include passage, across
openings in tight junctions, of serum proteins that may be
Box 2. Outstanding questions
 How can invading extracellular pathogens, such as trypanosomes,
hijack the precisely regulated multi-step infiltration of white blood
cells across the BBB, and by which mechanisms can the BBB
gateway be closed behind entering cells?
 How is trafficking of pathogens and inflammatory cells within the
brain parenchyma regulated while they criss-cross the sensitive
nervous tissue?
 How are the immune responses in the brain switched on and off
to balance effects on invading microbes and the nervous tissue?
Which factors can tilt the balance to elicit relapse of infections,
recovery, or irreversible post-inflammatory reactions?
 Which inflammatory mediators in cerebral endothelial cells,
pericytes, and macrophages/microglia contribute to neurodegen-
eration or protect against it? Can safe anti-inflammatory therapies
of brain infectious diseases be designed to kill the pathogen while
promoting the survival of neurons?
 Do astrocytic endfeet at the BBB bridge interactions between
synaptic activities and cerebral endothelial immune reactions, i.e.,
do synaptic activity and immune responses interact for reciprocal
regulation during infection/inflammation?
 Can transcytosis in cerebral endothelial cells be manipulated to
promote selective delivery of drugs across the BBB? Can
transporter ligands that efficiently detach after BBB crossing [91]
be developed? Can pericytes be targets for therapies that aim at
inhibiting microbe invasion and promote targeted drug delivery to
the brain?
Review Trends in Neurosciences June 2014, Vol. 37, No. 6toxic to neurons, diminished brain capillary perfusion
leading to hypoxia, and loss of pericyte-derived trophic
molecules that promote the survival of cerebral endothelial
cells [59,63–66].
In contrast to these observations, extensive clinical
search for signs of increased BBB permeability by CSF/
serum protein as well as histological and neuroimaging
studies in patients affected by Alzheimer’s disease (AD)
have failed to provide clear-cut evidence for BBB disrup-
tion in this major neurodegenerative disease [67]. Howev-
er, several findings point to a dysfunction at the level of
transcytosis across the BBB of amyloid-b (Ab) molecules,
which are thought to play a pathogenetic role in AD. Such
dysfunction could lead to accumulation of misfolded Ab
around intracerebral vessels, reflecting either a deficit in
Ab clearance from the brain across the BBB or an in-
creased influx from the blood. Lipoprotein receptor-related
protein 1 (LRP-1) [68] and the multidrug transporter P
protein (Pgp) [69,70] can both promote Ab efflux into the
bloodstream, whereas the receptor for advanced glycation
endproducts (RAGE) can transport soluble Ab from the
blood into the brain [71]. A disturbed balance between
these influx and efflux processes could lead to pathological
accumulation of toxic Ab peptides in the brain and has
therefore been implicated in AD pathogenesis [67,72].
However, Ab may also be cleared from the brain through
other mechanisms. For instance, the soluble Ab form can
be cleared experimentally from the brain through para-
venous spaces to the CSF rather than across the BBB [41].
Ab clearance could also occur along the above-mentioned
cerebral arterial basement membranes [43].
Finally, concerning current challenges for mechanisms
of neurodegeneration, studies on trypanosome brain infec-
tions may be relevant for the extensive and longstanding
debate on the contribution of persistent or chronic inflam-
mation in the CNS to the pathogenesis of neurodegenera-
tive diseases [73,74]. Chronic trypanosome infections could
be of interest for studies on putative factors that may tilt
the balance towards neurotoxicity or neuroprotection. For
example, aspirin (sodium salicylate) treatment exacer-
bates brain neurodegeneration in trypanosome-infected
rats [75], demonstrating that chronic neuroinflammation
can be neuroprotective.
Concluding remarks
Inflammatory cells and molecules trafficking to, within,
and out of the brain, as discovered by the use of African
trypanosomes and trypan dyes 100 years ago, have now
reached the frontline of research on brain disorders, rais-
ing many questions (Box 2). Neuroinflammation, a term
introduced only 20 years ago, is thereby currently on stage
due to its importance in healthy brain aging and in neuro-
degenerative diseases, whereas the field of brain infections
is relatively neglected in neuroscience, considered mainly a
domain of microbiology. However, the fight between a
competent BBB and pathogens searching for secure niches
in the brain microenvironment, where they can escape the
bullets of the immune system, has yielded key insight into
CNS health and disease. Interestingly, these studies can
contribute to unravelling mechanisms by which T cells can
pave the way to BBB crossing of other elements, as well asmechanisms by which cells could exit the brain, and those
by which inflammation could be switched off.
Last but not least, targeted brain delivery of drugs
(Ehrlich’s ‘bewitched bullets’) is still an open field of active
investigation, using, for example, nanobodies or nanopar-
ticles as minute carriages to fool the BBB drawbridge (Box
1). However, despite this progress, safe and effective ther-
apies for brain involvement in African trypanosomiasis
remain to be found after more than a century.
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